Viatris Sante Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: Viatris Sante Pharmaceutical Import Records from India — 3 Products, $2.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Viatris Sante — Pharmaceutical Importer Profile (2026) | 3 Products, $2.7M Trade | TransData Nexus

Viatris Sante

Pharmaceutical Importer · France · Diuretics Focus · $2.7M Total Trade · DGFT Verified

Viatris Sante is a pharmaceutical importer based in France with a total trade value of $2.7M across 3 products in 3 therapeutic categories. Based on 56 verified import shipments from Indian Customs (DGFT) records, Viatris Sante is the #1 buyer in 1 product including Ibuprofen. Viatris Sante sources from 9 verified Indian suppliers, with Mylan Laboratories Limited accounting for 79.2% of imports.

Viatris Sante — Import Portfolio & Supplier Network

Viatris Sante import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Viatris Sante?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$43.0M	1,587	79.2%
Granules India Limited	$6.2M	224	11.3%
Lupin Limited	$2.6M

What Formulations Does Viatris Sante Import?

Formulation	Value	Ships
Levetiracetam mylan phar 500MG 2000s	$800.0K	16
Metformine viatris 500 MG, 6x15's-viatris/france metformine hcl mylan 500 MG(15x6)	$765.2K	31
Metformine viatris 850 MG, 6x15's-viatris/france metformine mylan pharma 850 MG(15x6)	$677.3K	18
Metformine viatris 1000 MG, 6x15's-viatris/france metformine mylan pharma 1000 MG(15x6)	$663.1K	20
Clopidogrel/acide acetylsalicylique	$500.0K	10
Metformine viatris 500 MG, 2x15's-viatris/france metformine mylan pharma 500 MG(15x2)	$471.3K	25
Metformine viatris 1000 MG, 6x15's-viatris/france metformine mylan pharma 1000 MG(15x6	$407.6K	18
Irbesartan / hydrochlorothiazide mylan	$382.9K	8
Levetiracetam mylan phar 250MG 4000s	$346.3K	16
Metformine viatris 850 MG, 6x15's-viatris/france metformine mylan pharma 850 MG(15x6)	$305.9K	8
Harmless medicines, mianserin	$263.4K	7
Harmless medicines, trimebutine 200MG	$260.6K	7
Irbesartan / hydrochlorothiazide mylan	$256.5K	6
Divalcote ge 500MG TAB 90's valproate semisodium Gastro-Resistant	$250.0K	5
Metformine viatris 1000 MG 6x15's-viatris/france metformine mylan pharma 1000 MG(15x6)	$245.7K	5

Viatris Sante imports 1,159 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Furosemide	Diuretics	$1.6M	33	2.2%	7
2	Loratadine	Antihistamines & Allergy	$900.0K	18	0.5%	10
3	Ibuprofen	Analgesics & Antipyretics	$250.0K	5	0.0%	1

Viatris Sante imports 3 pharmaceutical products across 3 categories into France totaling $2.7M. The company is the #1 buyer for 1 product: Ibuprofen.

Viatris Sante — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Viatris Santé is a prominent pharmaceutical importer and buyer based in Lyon, France. As a subsidiary of Viatris Inc., a global healthcare company formed through the merger of Mylan and Upjohn in November 2020, Viatris Santé plays a pivotal role in the French pharmaceutical distribution network. The company is dedicated to providing access to high-quality medicines across a broad spectrum of therapeutic areas, ensuring that patients in France receive essential treatments. (viatris.fr)

Viatris Santé's operations encompass the importation and distribution of a diverse range of pharmaceutical products, including both branded and generic medications. The company's extensive portfolio covers approximately 450 molecules across 1,500 references, addressing various health conditions from acute illnesses to chronic diseases. (viatris.fr) This comprehensive approach underscores Viatris Santé's commitment to enhancing patient access to essential healthcare solutions throughout France.

2Distribution Network

Viatris Santé's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across France. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive reach indicates a well-established infrastructure capable of meeting the diverse needs of the French healthcare system. Viatris Santé's operations are integrated within Viatris Inc.'s global supply chain, leveraging the corporation's manufacturing capabilities and distribution channels to maintain a reliable supply of medicines.

3Industry Role

In the French pharmaceutical supply chain, Viatris Santé functions primarily as a pharmaceutical importer and distributor. The company imports a wide array of pharmaceutical formulations from various global suppliers, including Indian manufacturers, and distributes these products to pharmacies, hospitals, and other healthcare providers throughout France. This role is crucial in ensuring the availability of both branded and generic medications, thereby supporting the French healthcare system's capacity to deliver comprehensive patient care.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Viatris Sante

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Viatris Santé's sourcing strategy reveals a significant concentration in its supplier base, particularly from Indian pharmaceutical manufacturers. The company's total import value from India amounts to $2.7 million USD, encompassing 56 shipments and 1,159 unique formulations. The top three suppliers—Mylan Laboratories Limited, Granules India Limited, and Lupin Limited—account for a substantial portion of these imports, indicating a strategic reliance on these partners. This concentration suggests a deliberate sourcing approach aimed at ensuring product quality and supply chain efficiency.

However, such dependency on a limited number of suppliers may pose risks related to supply chain disruptions, regulatory changes, or geopolitical factors affecting trade relations. To mitigate these risks, Viatris Santé may consider diversifying its supplier base and establishing contingency plans to maintain a steady supply of essential medications.

2Supply Chain Resilience

Viatris Santé's supply chain resilience is closely tied to the stability and reliability of its Indian suppliers. The company's significant import volume from India underscores the importance of these suppliers in meeting the demand for pharmaceutical products in France. While the concentration of suppliers may enhance operational efficiency, it also exposes Viatris Santé to potential risks associated with supply chain disruptions. To bolster resilience, the company could explore partnerships with additional suppliers and develop alternative sourcing strategies to ensure uninterrupted access to critical medications.

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the French National Agency for Medicines and Health Products Safety (ANSM). The ANSM is responsible for ensuring the safety, efficacy, and quality of health products available in the French market. Key legislation governing pharmaceutical imports includes the Public Health Code, which outlines the requirements for marketing authorization, importation, and distribution of medicinal products.

For Indian generics to be marketed in France, they must undergo a marketing authorization process, which can be obtained through the European Medicines Agency (EMA) or via national procedures. The EMA provides centralized marketing authorization for medicinal products, allowing them to be marketed across all EU member states, including France. This process involves rigorous evaluation of the product's quality, safety, and efficacy data.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in France are stringent. Importers must hold a wholesale distribution authorization issued by the ANSM, which ensures compliance with Good Distribution Practice (GDP) standards. Additionally, imported pharmaceutical products must be manufactured in facilities that comply with Good Manufacturing Practice (GMP) standards recognized by the European Union, the World Health Organization (WHO), or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications are essential to guarantee the quality and safety of medicinal products entering the French market.

Viatris Sante — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Viatris Santé's focus on importing products in the therapeutic categories of diuretics, antihistamines, and analgesics aligns with prevalent health concerns in France. The significant importation of furosemide, loratadine, and ibuprofen indicates a strategic emphasis on addressing conditions such as hypertension, allergies, and pain management. This product strategy reflects an understanding of the French market's needs and positions Viatris Santé to effectively meet patient demands in these areas.

2Sourcing Profile

Viatris Santé's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from India, focusing on products that are in high demand within the French market. The company's preference for sourcing from India is likely due to the country's robust pharmaceutical manufacturing capabilities, cost-effectiveness, and the availability of a wide range of generic medications. This approach enables Viatris Santé to offer a diverse and affordable product portfolio to the French healthcare system.

3Market Positioning

Based on its product mix, Viatris Santé serves multiple segments of the French pharmaceutical market, including retail pharmacies, hospitals, and wholesale distribution channels. The company's extensive portfolio and distribution capabilities allow it to cater to a broad spectrum of healthcare providers, ensuring that patients across France have access to essential medications.

Seller's Guide — How to Become a Supplier to Viatris Sante

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Viatris Santé, particularly if they can offer products that complement the existing portfolio and meet the regulatory standards required for the French market. Identifying gaps in Viatris Santé's current sourcing, such as unmet therapeutic needs or emerging health concerns, could present avenues for new suppliers to introduce innovative solutions.

2Requirements & Qualifications

Indian exporters aiming to supply Viatris Santé and the French market must ensure that their products comply with EU GMP standards and possess the necessary marketing authorizations. Additionally, they must adhere to French labeling requirements, including French language labeling and serialization mandates. Establishing a wholesale distribution authorization with the ANSM is also essential for legal importation and distribution within France.

3How to Approach

Indian exporters should initiate the relationship by demonstrating their compliance with EU GMP standards and providing evidence of successful regulatory approvals in other EU markets. Participating in relevant tenders and engaging in direct communication with Viatris Santé can facilitate partnership opportunities. Developing a comprehensive regulatory filing strategy, including the preparation of dossiers for marketing authorization applications, and understanding the typical timelines for approval processes in France are crucial steps in establishing a successful partnership.

Frequently Asked Questions — Viatris Sante

What products does Viatris Sante import from India?

Viatris Sante imports 3 pharmaceutical products across 3 categories. Top imports: Furosemide ($1.6M), Loratadine ($900.0K), Ibuprofen ($250.0K).

Who supplies pharmaceuticals to Viatris Sante from India?

Viatris Sante sources from 9 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (79.2% of imports, $43.0M).

What is Viatris Sante's total pharmaceutical import value?

Viatris Sante's total pharmaceutical import value from India is $2.7M, based on 56 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Viatris Sante focus on?

Viatris Sante imports across 3 categories. The largest: Diuretics (57.9%), Antihistamines & Allergy (33.0%), Analgesics & Antipyretics (9.2%).

Get Full Viatris Sante Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.